

Danny Rischin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4008374/publications.pdf>

Version: 2024-02-01

174
papers

16,874
citations

39113

52
h-index

17373

126
g-index

174
all docs

174
docs citations

174
times ranked

16645
citing authors

#	ARTICLE	IF	CITATIONS
1	Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 2237-2246.	0.8	2,822
2	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 1915-1928.	6.3	1,804
3	PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 341-351.	13.9	997
4	Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02. <i>Journal of Clinical Oncology</i> , 2010, 28, 2996-3001.	0.8	683
5	Prognostic Significance of p16 ^{INK4A} and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 4142-4148.	0.8	679
6	Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography-Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02. <i>Journal of Clinical Oncology</i> , 2006, 24, 2098-2104.	0.8	532
7	Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor Inhibition. <i>Journal of Clinical Oncology</i> , 2002, 20, 110-124.	0.8	441
8	Positron Emission Tomography Is Superior to Computed Tomography Scanning for Response-Assessment After Radical Radiotherapy or Chemoradiotherapy in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 1285-1292.	0.8	414
9	Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2009, 27, 1864-1871.	0.8	353
10	Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 2989-2995.	0.8	339
11	Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. <i>Seminars in Cancer Biology</i> , 2018, 52, 228-240.	4.3	314
12	Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. <i>Lancet Oncology</i> , The, 2020, 21, 294-305.	5.1	304
13	High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study-TROG 96:07. <i>Journal of Clinical Oncology</i> , 2003, 21, 4371-4376.	0.8	252
14	Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel. <i>Gynecologic Oncology</i> , 1996, 63, 89-93.	0.6	238
15	Tirapazamine, Cisplatin, and Radiation Versus Fluorouracil, Cisplatin, and Radiation in Patients With Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). <i>Journal of Clinical Oncology</i> , 2005, 23, 79-87.	0.8	237
16	A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 119, 32-37.	0.6	228
17	F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma. <i>Cancer</i> , 2001, 92, 886-895.	2.0	221
18	IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 2538-2548.	3.2	217

#	ARTICLE	IF	CITATIONS
19	An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin. <i>Cancer Research</i> , 2005, 65, 4031-4040.	0.4	206
20	The "QUAD SHOT" a phase II study of palliative radiotherapy for incurable head and neck cancer. <i>Radiotherapy and Oncology</i> , 2005, 77, 137-142.	0.3	201
21	Phase I Trial of Concurrent Tirapazamine, Cisplatin, and Radiotherapy in Patients With Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 535-542.	0.8	183
22	Survival with Cemiplimab in Recurrent Cervical Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 544-555.	13.9	182
23	Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 114-119.	0.4	164
24	Prospective study of percutaneous endoscopic gastrostomy tubes versus nasogastric tubes for enteral feeding in patients with head and neck cancer undergoing (chemo)radiation. <i>Head and Neck</i> , 2009, 31, 867-876.	0.9	156
25	Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 3152-3161.	0.8	153
26	Phase II study of imatinib in patients with small cell lung cancer. <i>Clinical Cancer Research</i> , 2003, 9, 5880-7.	3.2	145
27	Excellent Disease Control and Survival in Patients With Advanced Nasopharyngeal Cancer Treated With Chemoradiation. <i>Journal of Clinical Oncology</i> , 2002, 20, 1845-1852.	0.8	135
28	Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1384-1391.	3.3	135
29	Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1275-1283.	0.8	134
30	Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment Study. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1616-1622.	0.5	121
31	Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. , 2020, 8, e000775.		113
32	N2-N3 neck nodal control without planned neck dissection for clinical/radiologic complete responders"Results of Trans Tasman Radiation Oncology Group Study 98.02. <i>Head and Neck</i> , 2008, 30, 737-742.	0.9	109
33	Promising results with chemoradiation in patients with sinonasal undifferentiated carcinoma. <i>Head and Neck</i> , 2004, 26, 435-441.	0.9	108
34	Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. <i>Clinical Cancer Research</i> , 2017, 23, 1862-1874.	3.2	107
35	Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1-Amplified Ovarian Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5960-5971.	3.2	97
36	Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. <i>Lancet Oncology</i> , The, 2020, 21, e350-e359.	5.1	96

#	ARTICLE	IF	CITATIONS
37	Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 295-304.	1.6	93
38	Impact of Positron Emission Tomography on the Management of Patients With Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 164-171.	0.6	86
39	A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 791-801.	1.1	86
40	Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1230-1237.	1.1	84
41	Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). <i>Frontiers in Oncology</i> , 2016, 6, 232.	1.3	82
42	Oropharyngeal Cancer, Human Papilloma Virus, and Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1-3.	0.8	78
43	The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. <i>Head and Neck</i> , 2003, 25, 138-145.	0.9	77
44	Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) â€” A Trans-Tasman Radiation Oncology Group Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 876-886.	0.4	68
45	Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. <i>Cancer Research</i> , 2015, 75, 4211-4223.	0.4	65
46	How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?. <i>Cancer</i> , 2007, 109, 117-124.	2.0	60
47	Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, 3270-3277.	0.8	60
48	Optimising the therapeutic ratio in head and neck cancer. <i>Lancet Oncology</i> , The, 2010, 11, 287-291.	5.1	59
49	What is the best treatment for patients with human papillomavirusâ€”positive and â€”negative oropharyngeal cancer?. <i>Cancer</i> , 2014, 120, 1462-1470.	2.0	58
50	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. <i>Clinical Cancer Research</i> , 2020, 26, 5153-5161.	3.2	58
51	De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. <i>Journal of Clinical Oncology</i> , 2020, 38, 2552-2557.	0.8	58
52	Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1798-1807.	3.2	56
53	Imaging of hypoxia with ¹⁸ F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2013, 57, 475-481.	0.9	55
54	Radiation with concurrent late chemotherapy intensification (â€”chemoboostâ€™) for locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2000, 54, 123-127.	0.3	54

#	ARTICLE	IF	CITATIONS
55	Merkel Cell Carcinoma: Emerging Biology, Current Approaches, and Future Directions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e519-e526.	1.8	54
56	Differential mechanisms of <i>CDKN2A</i> (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. International Journal of Cancer, 2014, 135, 887-895.	2.3	53
57	Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. European Journal of Cancer, 2018, 105, 88-102.	1.3	53
58	PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Gynecologic Oncology, 2020, 159, 322-328.	0.6	51
59	Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation. Clinical Cancer Research, 2011, 17, 5152-5160.	3.2	49
60	Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anti-Cancer Drugs, 2008, 19, 547-552.	0.7	48
61	Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial. Clinical Cancer Research, 2012, 18, 301-307.	3.2	47
62	Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. , 2021, 9, e002757.		46
63	Current Hepatitis B Screening Practices and Clinical Experience of Reactivation in Patients Undergoing Chemotherapy for Solid Tumors: A Nationwide Survey of Medical Oncologists. Journal of Oncology Practice, 2011, 7, 141-147.	2.5	45
64	High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 527-533.	0.7	42
65	Weekly Carboplatin Reduces Toxicity During Synchronous Chemoradiotherapy for Merkel Cell Carcinoma of Skin. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1070-1074.	0.4	41
66	Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). International Journal of Radiation Oncology Biology Physics, 2017, 97, 678-686.	0.4	41
67	FDG-PET-Detected Extracranial Metastasis in Patients with Non-Small Cell Lung Cancer Undergoing Staging for Surgery or Radical Radiotherapy. Acta Oncologica, 2003, 42, 48-54.	0.8	40
68	p16-positive lymph node metastases from cutaneous head and neck squamous cell carcinoma: No association with high-risk human papillomavirus or prognosis and implications for the workup of the unknown primary. Cancer, 2016, 122, 1201-1208.	2.0	40
69	Overview of Advances in Head and Neck Cancer. Journal of Clinical Oncology, 2015, 33, 3225-3226.	0.8	39
70	Tonsillar cancer: The Peter MacCallum experience with unilateral and bilateral irradiation. Head and Neck, 2014, 36, 317-322.	0.9	38
71	BRAF Inhibition in <i>BRAF</i> ^{V600E} -Positive Anaplastic Thyroid Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 249-254.	2.3	38
72	Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. Future Oncology, 2020, 16, 1235-1243.	1.1	36

#	ARTICLE	IF	CITATIONS
73	Correlation of p16 status, hypoxic imaging using [18F]misonidazole positron emission tomography and outcome in patients with locally advanced head and neck cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 89-97.	0.9	35
74	Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10018-10018.	0.8	34
75	Hypoxia in Head and Neck Cancer: Studies With Hypoxic Positron Emission Tomography Imaging and Hypoxic Cytotoxins. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S61-S63.	0.4	32
76	Non-smoking, non-drinking elderly females, a 5-year follow-up of a clinically distinct cohort of oral squamous cell carcinoma patients. <i>Oral Oncology</i> , 2018, 86, 113-120.	0.8	31
77	Quality of Life, Toxicity and Unmet Needs in Nasopharyngeal Cancer Survivors. <i>Frontiers in Oncology</i> , 2020, 10, 930.	1.3	31
78	Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. <i>Clinical Cancer Research</i> , 2003, 9, 2040-8.	3.2	31
79	Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 39, 557-560.	1.1	30
80	Suboptimal health literacy in patients with lung cancer or head and neck cancer. <i>Supportive Care in Cancer</i> , 2013, 21, 2237-2245.	1.0	30
81	Frequency of Fibroblast Growth Factor Receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome. <i>Oral Oncology</i> , 2013, 49, 576-581.	0.8	30
82	Recent Insights and Advances in the Management of Merkel Cell Carcinoma. <i>Journal of Oncology Practice</i> , 2016, 12, 637-646.	2.5	30
83	The role of human papillomavirus in p16-positive oral cancers. <i>Journal of Oral Pathology and Medicine</i> , 2018, 47, 18-24.	1.4	29
84	Strategies to overcome accelerated repopulation and hypoxia—what have we learned from clinical trials?. <i>Seminars in Oncology</i> , 2004, 31, 802-808.	0.8	28
85	A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2013, 49, 468-474.	0.8	28
86	Phase 1 Study of Tirapazamine in Combination With Radiation and Weekly Cisplatin in Patients With Locally Advanced Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 827-833.	1.2	27
87	Quantitative and qualitative analysis of [18F]FDG and [18F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 617-625.	3.3	26
88	A phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2004, 93, 417-421.	0.6	23
89	The Utility of 2-Deoxy-2-[F-18]fluoro-d-glucose Positron Emission Tomography in the Investigation of Patients with Disseminated Carcinoma of Unknown Primary Origin. <i>Molecular Imaging and Biology</i> , 2005, 7, 236-243.	1.3	23
90	Sinonasal Malignancies of Neuroendocrine Origin. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 1297-1316.	0.9	22

#	ARTICLE	IF	CITATIONS
91	18F-FDG PET/CT following chemoradiation of uterine cervix cancer provides powerful prognostic stratification independent of HPV status: a prospective cohort of 105 women with mature survival data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1825-1832.	3.3	21
92	Oral cyclophosphamide in recurrent ovarian cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, e154-60.	0.7	21
93	PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2016, 38, E1756-61.	0.9	20
94	Rectal adenocarcinoma with germ cell elements treated with chemotherapy. <i>Pathology</i> , 1993, 25, 243-246.	0.3	20
95	Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome. <i>Clinical Epigenetics</i> , 2014, 6, 22.	1.8	19
96	Safety and cost analysis of an 18FDG-PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation. <i>Oral Oncology</i> , 2015, 51, 529-535.	0.8	19
97	The role of PET-CT in the management of patients with advanced cancer of the head and neck. <i>Current Oncology Reports</i> , 2008, 10, 149-155.	1.8	18
98	Developing a Performance Data Suite to Facilitate Lean Improvement in a Chemotherapy Day Unit. <i>Journal of Oncology Practice</i> , 2013, 9, e115-e121.	2.5	18
99	Treatment response in the neck: p16+ versus p16- oropharyngeal cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2013, 57, 364-372.	0.9	18
100	Abiraterone in Metastatic Salivary Duct Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 288-290.	2.3	18
101	Promising Results of a Cooperative Group Phase II Trial of Preoperative Chemoradiation for Locally Advanced Rectal Cancer (TROG 9801). <i>Diseases of the Colon and Rectum</i> , 2005, 48, 1389-1396.	0.7	17
102	T4 squamous cell carcinoma of the oral tongue without mandibular involvement: surgery or chemoradiotherapy?. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014, 117, 163-169.	0.2	17
103	Validation and characterisation of prognostically significant PD-L1+ immune cells in HPV+ oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 101, 104516.	0.8	17
104	Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. <i>Oral Oncology</i> , 2022, 128, 105815.	0.8	17
105	Subxiphoid partial pericardiectomy with or without sclerosant instillation in the treatment of symptomatic pericardial effusions in patients with malignancy. <i>Cancer</i> , 1991, 68, 1021-1025.	2.0	16
106	Elusive Goal of Targeting Tumor Hypoxia for Therapeutic Gain. <i>Journal of Clinical Oncology</i> , 2012, 30, 1741-1743.	0.8	16
107	A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 130-139.	0.5	16
108	Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , 2021, 26, e1508-e1513.	1.9	16

#	ARTICLE	IF	CITATIONS
109	Larynx Preservation for Patients With Locally Advanced Laryngeal Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 840-844.	0.8	15
110	Health-Related Quality of Life, Psychosocial Distress and Unmet Needs in Older Patients With Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 834068.	1.3	15
111	Prolonged Remission in a Patient With Nasopharyngeal Carcinoma With a Solitary Bone Metastasis. <i>Journal of Clinical Oncology</i> , 2011, 29, e135-e137.	0.8	13
112	Fear of Cancer Recurrence in Survivors of Human Papillomavirus-Associated Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 890-899.	0.4	12
113	Repetitive High-Dose Topotecan, Carboplatin, and Paclitaxel with Peripheral Blood Progenitor Cell Support in Previously Untreated Ovarian Cancer: Results of a Phase I Study. <i>Gynecologic Oncology</i> , 2001, 81, 216-224.	0.6	11
114	<i>Pneumocystis jirovecii</i> pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis. <i>Leukemia and Lymphoma</i> , 2015, 56, 157-162.	0.6	11
115	Unilateral radiotherapy treatment for p16/human papillomavirus-positive squamous cell carcinoma of unknown primary in the head and neck. <i>Laryngoscope</i> , 2018, 128, 2076-2083.	1.1	11
116	FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma. <i>Cancer Imaging</i> , 2021, 21, 57.	1.2	11
117	Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 796197.	1.3	11
118	Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2012, 48, 698-702.	0.8	10
119	Weekly cisplatin and radiotherapy for low risk, locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1117-21.	0.9	10
120	Impact of histological Oral Tongue Cancer margins on locoregional recurrence: A multi-centre retrospective analysis. <i>Oral Oncology</i> , 2020, 111, 105004.	0.8	10
121	Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2020, 21, 85-90.	0.9	10
122	Sexual Health and Interpersonal Relationships After Chemoradiation Therapy for Human Papillomavirus-Associated Oropharyngeal Cancer: A Cross-sectional Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 382-393.	0.4	10
123	Patient-reported quality of life and symptom burden measures in human papillomavirus associated oropharyngeal cancer – A review of the literature and PRO methodology. <i>Oral Oncology</i> , 2021, 118, 105309.	0.8	10
124	Phase II Trial of Continuous Infusion Carboplatin, 5-Fluorouracil, and Radiotherapy for Localized Cancer of the Esophagus. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 277-282.	0.6	9
125	The Local-Regionally Advanced Nasopharyngeal Carcinoma Jigsaw Puzzle: Where Does the Chemotherapy Piece Fit?. <i>Journal of Clinical Oncology</i> , 2002, 20, 1968-1970.	0.8	8
126	Larynx preservation with primary non-surgical treatment for locoregionally advanced larynx cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2011, 55, 229-235.	0.9	8

#	ARTICLE	IF	CITATIONS
127	Ovarian Growing Teratoma Syndrome With Spuriously Elevated β -Fetoprotein. <i>Journal of Clinical Oncology</i> , 2015, 33, e99-e100.	0.8	8
128	Genome-scale methylation assessment did not identify prognostic biomarkers in oral tongue carcinomas. <i>Clinical Epigenetics</i> , 2016, 8, 74.	1.8	8
129	Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation. <i>Clinical and Translational Radiation Oncology</i> , 2017, 2, 53-58.	0.9	8
130	Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCMA β , ζ system in a quaternary oncology centre. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 865-876.	1.1	8
131	Carboplatin dosing in the era of IDMS-creatinine; the Cockcroft-Gault formula no longer provides a sufficiently accurate estimate of glomerular filtration rate for routine use in clinical care. <i>Gynecologic Oncology</i> , 2020, 157, 793-798.	0.6	8
132	Review : Cremophor: Pharmacological activity of an "inert" solubiliser. <i>Journal of Oncology Pharmacy Practice</i> , 1997, 3, 186-192.	0.5	7
133	Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG. <i>Oral Oncology</i> , 2017, 71, 180-183.	0.8	7
134	Burden and clinical outcomes of hospital-coded infections in patients with cancer: an 11-year longitudinal cohort study at an Australian cancer centre. <i>Supportive Care in Cancer</i> , 2020, 28, 6023-6034.	1.0	7
135	Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis. <i>Advances in Therapy</i> , 2021, 38, 2365-2378.	1.3	7
136	A randomized cross-over trial to determine the effect of Cremophor EL on the pharmacodynamics and pharmacokinetics of carboplatin chemotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 407-414.	1.1	6
137	Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5645.	1.7	6
138	A randomised controlled trial of clinical pharmacy intervention versus standard care to improve medication adherence in outpatients with head and neck cancer receiving radiotherapy. <i>Supportive Care in Cancer</i> , 2022, 30, 4243-4253.	1.0	6
139	Merkel cell carcinoma " current therapeutic options. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 2187-2192.	0.9	5
140	Induction chemotherapy in head and neck cancer: closer to an answer?. <i>Lancet Oncology</i> , The, 2011, 12, 113-114.	5.1	5
141	High-Dose Cisplatin for Head and Neck Cancer Lives On. <i>Journal of Clinical Oncology</i> , 2018, 36, 1055-1057.	0.8	5
142	Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocol. <i>BMC Health Services Research</i> , 2021, 21, 513.	0.9	5
143	A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS10084-TPS10084.	0.8	5
144	A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. <i>Investigational New Drugs</i> , 2022, 40, 782-788.	1.2	5

#	ARTICLE	IF	CITATIONS
145	Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials. <i>Annals of Oncology</i> , 2022, 33, 804-813.	0.6	5
146	Prospective Study of Cetuximab, Carboplatin, and Radiation Therapy for Patients With Locally Advanced Head and Neck Squamous Cell Cancer Unfit for Cisplatin. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 948-954.	0.4	4
147	Validation of local p16 testing for determination of human papilloma virus status eligibility on a low risk oropharyngeal cancer trial "A Trans-Tasman Radiation Oncology Group study. <i>Oral Oncology</i> , 2020, 110, 104988.	0.8	4
148	Pseudotumor presentation of CMV disease: Diagnostic dilemma and association with immunomodulating therapy. <i>Transplant Infectious Disease</i> , 2021, 23, e13531.	0.7	4
149	Contralateral neck failure in oral tongue cancer: Outcomes from two centers using predefined treatment criteria. <i>Head and Neck</i> , 2021, 43, 2024-2031.	0.9	4
150	Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 656611.	1.3	4
151	Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6036-6036.	0.8	4
152	A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer. <i>Investigational New Drugs</i> , 1999, 17, 73-80.	1.2	3
153	Long-term survival following chemoradiation for inoperable non-small cell lung cancer. <i>Medical Journal of Australia</i> , 2008, 189, 557-559.	0.8	3
154	Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 97-105.	1.1	3
155	Radiation oncology outpatient medication management needs and service gaps "A cross-sectional study of patients and clinicians. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 846-852.	0.5	3
156	Symptom burden, quality of life, functioning and emotional distress in survivors of human papillomavirus associated oropharyngeal cancer: An Australian cohort. <i>Oral Oncology</i> , 2021, 122, 105560.	0.8	3
157	Cutaneous squamous cell carcinoma metastatic to the axilla and groin: Outcomes and prognostic factors. <i>Australasian Journal of Dermatology</i> , 2022, 63, 43-52.	0.4	3
158	A Phase II Trial of Carboplatin and Etoposide for Relapsed or Metastatic Carcinoma of the Cervix. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1998, 38, 87-90.	0.4	2
159	Comparison of self-reported smoking status and physician-recorded smoking status among patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). <i>Radiotherapy and Oncology</i> , 2011, 98, 143-144.	0.3	2
160	Surgical management of recurrent cutaneous squamous cell carcinoma of the head and neck after definitive surgery and radiotherapy. <i>ANZ Journal of Surgery</i> , 2020, 90, 1391-1395.	0.3	2
161	A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis. <i>Medical Journal of Australia</i> , 2001, 174, 312-313.	0.8	1
162	Promising New Approaches in the Treatment of Advanced Head and Neck Cancer. <i>American Journal of Cancer</i> , 2003, 2, 335-347.	0.4	1

#	ARTICLE	IF	CITATIONS
163	Outcomes of curative (chemo)radiotherapy for patients with non-p16 positive head and neck squamous cell carcinoma who are borderline for curative treatment. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 271-278.	0.9	1
164	Locoregional Radiation Therapy for De Novo Metastatic Nasopharyngeal Cancer: One Size Fits All?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 131-133.	0.4	1
165	Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients treated with cetuximab and radiotherapy on TROG 12.01 and De-ESCALaTE randomized trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, 109-109.	0.8	1
166	Impact of p16 status on the QOL effects of chemoradiation for locally advanced oropharynx cancer: Results of TROG 02.02.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5571-5571.	0.8	1
167	Transoral Surgery and Deintensified Adjuvant Therapy: Another Step in Determining Its Role in the Management of Human Papillomavirus Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2021, , JCO2102364.	0.8	1
168	Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up. <i>SKIN the Journal of Cutaneous Medicine</i> , 2020, 4, s124.	0.1	1
169	A clinical trial with protracted infusion 5-fluorouracil and mitomycin C for localized squamous cell carcinoma of the anus. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 15, 75-81.	0.7	0
170	A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 613-620.	1.1	0
171	The Clinical Impact of Hypoxia in Head and Neck Squamous Cell Carcinoma. <i>Current Cancer Research</i> , 2018, , 397-438.	0.2	0
172	Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	0
173	C-POST protocol update: A phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9592-TPS9592.	0.8	0
174	Staging locally advanced cervical cancer with FIGO 2018 versus FIGO 2008: Impact on overall survival and progression-free survival in the OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5531-5531.	0.8	0